PE-22-28.png
PE-22-28.png
PE-22-28.png
PE-22-28.png

PE-22-28 (8mg)

$60.00

Quantity:
Add To Cart

PE-22-28 is an advanced peptide treatment designed to address depression and stimulate neurogenesis and synaptogenesis, particularly in the hippocampus. It offers a promising alternative to traditional antidepressants with fewer side effects. PE-22-28 remains effective in antagonizing TREK-1, even after modifications aimed at extending its half-life or changing its administration route. This peptide is not only advancing the development of new antidepressants but is also contributing to treatments for neurodegenerative conditions such as Alzheimer’s disease.

Common Indications/Treatments

  • Depression: Provides relief from depressive symptoms

  • Post-Stroke Depression (PSD): Aids in recovery from depression following a stroke

  • Neurogenesis Improvement: Enhances the growth of new neurons

What You Need to Know

PE-22-28 is a key player in the evolving field of nootropics and antidepressant development, offering a novel approach to mental health and neurodegenerative disease treatment.

DISCLAIMER: FOR EXPERIMENTAL USE ONLY, NOT FOR PERSONAL USE